Pharmaceutical manufacturers, especially those working with time-sensitive precision medicines and cell therapies, could soon see faster release times thanks to Sapho Bio. The biotechnology company, which is developing a rapid microbiology release platform, has just closed a $5.0M seed round.
Sapho Bio's initial focus is on rapid sterility testing, a critical bottleneck in drug production. The new capital will accelerate the development of its platform, which aims to offer a broader suite of rapid microbiology solutions beyond its initial sterility testing kit.
